SIERRA研究:STRIDE方案一线治疗预后不良不可切除肝细胞癌
SIERRA是一项IIIb期单臂研究,纳入111例预后不良的不可切除肝细胞癌患者(Child-Pugh B7/B8、ECOG PS 2或Vp4),接受STRIDE方案治疗。主要终点为6个月内3/4级治疗相关不良事件发生率和客观缓解率,结果分别为19.8%和14.4%,提示该人群风险获益良好。
要点
- STRIDE方案在预后不良uHCC中6个月内3/4级PRAE发生率为19.8%。
- 总人群ORR为14.4%,Child-Pugh B7/B8亚组仅6.8%。
- ECOG PS 2和Vp4亚组ORR分别为21.3%和15.0%。
核心结论
- SIERRA研究的安全性和有效性结果提示STRIDE方案在预后不良的uHCC人群中具有有利的风险获益特征。
研究设计与样本
- IIIb期单臂研究(NCT05883644),纳入111例预后不良的不可切除肝细胞癌成人患者。
- 患者分为三个队列:Child-Pugh B7/B8(n=44)、ECOG PS 2(n=47)、Vp4(n=20)。
- 所有患者接受STRIDE方案:替西木单抗300 mg联合度伐利尤单抗1500 mg一次,随后度伐利尤单抗1500 mg每4周一次。
- 主要终点为治疗开始6个月内可能相关的3或4级不良事件发生率(Grade 3/4 PRAEs ≤6个月)和客观缓解率(ORR;数据截止2025年9月22日)。
主要发现
- 总人群6个月内3/4级PRAEs发生率为19.8%(95%CI 12.9-28.5)。
- Child-Pugh B7/B8亚组3/4级PRAEs发生率为18.2%(95%CI 8.2-32.7),ECOG PS 2亚组为19.1%(95%CI 9.1-33.3),Vp4亚组为25.0%(95%CI 8.7-49.1)。
- 总人群ORR为14.4%(95%CI 8.5-22.4)。
- Child-Pugh B7/B8亚组ORR为6.8%(95%CI 1.4-18.7),ECOG PS 2亚组为21.3%(95%CI 10.7-35.7),Vp4亚组为15.0%(95%CI 3.2-37.9)。
临床怎么用
- 对于预后不良的uHCC患者(如Child-Pugh B7/B8、ECOG PS 2或Vp4),STRIDE方案可作为一线治疗选择,但需密切监测毒性。
- Child-Pugh B7/B8患者ORR较低(6.8%),治疗决策时应充分评估获益与风险。
局限性
- 单臂研究设计,缺乏对照组,结论需谨慎解读。
- 样本量较小(总111例,Vp4亚组仅20例),亚组结果置信区间较宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Clinical trials in unresectable hepatocellular carcinoma (uHCC) often exclude patients with poor prognostic factors, including impaired liver function, poor functional status or main trunk portal vein thrombosis (Vp4). The dual immune checkpoint inhibitor regimen STRIDE (Single Tremelimumab Regular Interval Durvalumab) is a standard-of-care treatment for first-line uHCC. The phase IIIb SIERRA (NCT05883644) study previously reported early safety of STRIDE in participants of poor prognosis. Here, we present safety and efficacy results from the primary analysis of the SIERRA study. METHODS: Adults with uHCC with either Child-Pugh B7/B8 liver function (Child-Pugh B7/B8 cohort), Eastern Cooperative Oncology Group performance status 2 (ECOG PS 2 cohort) or Vp4 (Vp4 cohort) were enrolled. All participants received STRIDE (tremelimumab 300 mg plus durvalumab 1500 mg once, followed by durvalumab 1500 mg every 4 weeks) until disease progression, unacceptable toxicity or withdrawal. Primary endpoints were Grade 3 or 4 adverse events possibly related to study treatment within 6 months of treatment initiation (Grade 3/4 PRAEs ≤6 months) and objective response rate (ORR; data cut-off: 22 September 2025). RESULTS: In total, 111 participants were included (Child-Pugh B7/B8 n = 44, ECOG PS 2 n = 47, Vp4 n = 20). The incidence of Grade 3/4 PRAEs ≤6 months (95% confidence interval [CI]) was 19.8% (12.9-28.5): Child-Pugh B7/B8, 18.2% (8.2-32.7); ECOG PS 2, 19.1% (9.1-33.3); and Vp4, 25.0% (8.7-49.1). ORR (95% CI) was 14.4% (8.5-22.4): Child-Pugh B7/B8, 6.8% (1.4-18.7); ECOG PS 2, 21.3% (10.7-35.7); and Vp4, 15.0% (3.2-37.9). CONCLUSIONS: SIERRA safety and efficacy findings were indicative of a favourable risk-benefit profile for STRIDE in this participant population with a high unmet need. IMPACT AND IMPLICATIONS: Participants with poor prognosis (e.g. Child-Pugh B/C, Eastern Cooperative Oncology Group performance status >1 or main trunk portal vein thrombosis [Vp4]) remain underrepresented in global, phase III trials despite comprising up to 65% of patients with unresectable hepatocellular carcinoma (uHCC) in clinical practice. To address this unmet need, the phase IIIb SIERRA study (NCT05883644) evaluated STRIDE (Single Tremelimumab Regular Interval Durvalumab) in participants with poor prognostic factors. Safety and efficacy findings as per the co-primary endpoints are indicative of a favourable risk-benefit profile for STRIDE in this participant population with a high unmet need, with an incidence of Grade 3 or 4 PRAEs within 6 months of 19.8% and ORR of 14.4% in the total population. This is the first prospective interventional study to provide data informing the safety and efficacy of STRIDE in patients with uHCC in a previously underrepresented population of poor prognosis that are excluded from other phase III trials. CLINICAL TRIAL NUMBER: NCT05883644.
引用
- Chan SL, Kudo M, Sangro B, et al. First-line durvalumab and tremelimumab in poor-prognosis unresectable hepatocellular carcinoma: Phase IIIb single-arm SIERRA study. J Hepatol. 2026. PMID: 42838226. doi:10.1016/j.jhep.2026.10.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。